| Literature DB >> 34156453 |
Tatja Hirvikoski1,2,3, Marcus Boman4, Magnus Tideman5, Paul Lichtenstein4, Agnieszka Butwicka4,6,7.
Abstract
Importance: Knowledge of the health challenges and mortality in people with intellectual disability (ID) should guide health policies and practices in contemporary society. Objective: To examine premature mortality in individuals with ID. Design, Setting, and Participants: This population-based longitudinal cohort study obtained data from several national health care, education, and population registers in Sweden. Two registers were used to identify individuals with ID: the National Patient Register and the Halmstad University Register on Pupils With Intellectual Disability. Two cohorts were created: cohort 1 comprised young adults (born between 1980 and 1991) with mild ID, and cohort 2 comprised individuals (born between 1932 and 2013) with mild ID or moderate to profound ID; each cohort had matched reference cohorts. Data analyses were conducted between June 1, 2020, and March 31, 2021. Exposures: Mild or moderate to profound ID. Main Outcomes and Measures: The primary outcome was overall (all-cause) mortality, and the secondary outcomes were cause-specific mortality and potentially avoidable mortality.Entities:
Mesh:
Year: 2021 PMID: 34156453 PMCID: PMC8220491 DOI: 10.1001/jamanetworkopen.2021.13014
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Demographic Characteristics of Cohort 1: Young Adults With Mild Intellectual Disability (ID) and Their Matched Reference Cohort
| Characteristic | No. (%) | |
|---|---|---|
| Cohort 1: with mild ID | Matched reference cohort | |
| Total No. of individuals | 13 541 | 135 410 |
| Sex | ||
| Male | 7826 (57.8) | 78 260 (57.8) |
| Female | 5715 (42.2) | 57 150 (42.2) |
| Age at first ID diagnosis in the NPR, mean (SD) [range], y | 17.97 (5.82) [0.06-33.60] | NA |
| Age at finishing the USSID, mean (SD) [range], y | 20.60 (0.74) [18.04-23.96] | NA |
| No. of deaths | 120 (0.9) | 424 (0.3) |
| Age at death, y | ||
| All individuals | ||
| Mean (SD) | 24.53 (3.66) | 24.57 (3.00) |
| Median (range) | 24.22 (18.11-32.76) | 24.17 (18.10-32.71) |
| Male individuals | ||
| Mean (SD) | 25.24 (3.69) | 24.41 (2.97) |
| Median (range) | 25.36 (18.69-32.76) | 24.05 (18.10-32.71) |
| Female individuals | ||
| Mean (SD) | 23.64 (3.47) | 25.19 (3.05) |
| Median (range) | 23.57 (18.11-32.21) | 25.11 (18.61-32.14) |
| Parental educational level | ||
| High: academic | 2941 (21.7) | 60 103 (44.4) |
| Middle: upper secondary | 7912 (58.4) | 62 690 (46.3) |
| Low: elementary, ≤9 y compulsory | 1975 (14.6) | 8185 (6.0) |
| Missing data | 713 (5.3) | 4432 (3.3) |
| Coexisting diagnoses | ||
|
| 2887 (21.3) | 8373 (6.2) |
| Epilepsy | 1453 (10.7) | 1355 (1.0) |
| ASD and/or ADHD | 3492 (25.8) | 3815 (2.8) |
| Depression and/or anxiety | 2565 (18.9) | 11 712 (8.7) |
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; ICD-10 Chapter XVII: Chromosomal, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Chapter XVII: Congenital malformations, deformations, and chromosomal abnormalities; NA, not applicable; NPR, Swedish National Patient Register; USSID, upper secondary school for students with intellectual disability.
Risk of All-Cause, Cause-Specific, and Potentially Avoidable Mortality in Cohort 1: Young Adults With Mild Intellectual Disability (ID)
| Category | No./Total No. (%) | OR (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Cohort 1: with mild ID | Matched reference cohort | Crude | Parental educational level | Congenital malformations | Epilepsy | ASD and/or ADHD | Depression and/or anxiety | Adjusted for all potentially confounding factors | |
| Overall or all-cause mortality | |||||||||
| All individuals | 120/13 541 (0.9) | 424/135 410 (0.3) | 2.86 (2.33-3.50) | 2.77 (2.25-3.42) | 2.66 (2.15-3.28) | 2.25 (1.80-2.81) | 2.44 (1.94-3.06) | 2.37 (1.93-2.92) | 1.68 (1.31-2.15) |
| Male individuals | 67/7826 (0.9) | 338/78 260 (0.4) | 1.99 (1.53-2.60) | 1.91 (1.46-2.50) | 1.90 (1.45-2.49) | 1.64 (1.24-2.18) | 1.58 (1.17-2.12) | 1.63 (1.25-2.13) | 1.20 (0.87-1.64) |
| Female individuals | 53/5715 (0.9) | 86/57 150 (0.2) | 6.23 (4.42-8.79) | 6.31 (4.42-9.02) | 5.47 (3.82-7.85) | 4.58 (3.12-6.72) | 5.90 (4.08-8.54) | 5.28 (3.71-7.50) | 3.53 (2.30-5.42) |
| Cause-specific mortality by | |||||||||
| Chapter II: Neoplasms | 16/13 541 (0.1) | 45/135 410 (0.0) | 3.58 (2.02-6.35) | 3.26 (1.81-5.88) | 3.11 (1.72-5.64) | 3.00 (1.59-5.67) | 3.63 (1.96-6.70) | 3.71 (2.08-6.62) | 2.47 (1.21-5.02) |
| Chapter VI: Nervous system | 32/13 541 (0.2) | 8/135 410 (0.0) | 40.00 (18.43-86.80) | 47.15 (21.35-104.13) | 37.93 (17.19-83.69) | 15.61 (6.57-37.10) | 52.26 (23.64-115.56) | 37.96 (17.39-82.83) | 18.71 (7.62-45.98) |
| Chapter VI: Nervous system excluding individuals with epilepsy | 12/12 088 (0.1) | 8/120 880 (0.0) | 15.00 (6.13-36.69) | 17.25 (6.79-43.83) | 13.85 (5.46-35.13) | NA | 19.24 (7.60-48.70) | 12.67 (5.08-31.63) | 19.68 (7.26-53.38) |
| Chapter IX: Circulatory system | 17/13 541 (0.1) | 19/135 410 (0.0) | 9.24 (4.76-17.95) | 9.67 (4.84-19.32) | 8.14 (4.06-16.31) | 7.45 (3.66-15.13) | 10.09 (4.95-20.58) | 8.61 (4.38-16.93) | 6.64 (2.85-15.49) |
| Potentially avoidable mortality | |||||||||
| Potentially avoidable, both amenable and preventable | 71/13 541 (0.5) | 360/135 410 (0.3) | 1.98 (1.53-2.56) | 1.91 (1.47-2.48) | 1.91 (1.47-2.49) | 1.57 (1.19-2.07) | 1.51 (1.13-2.00) | 1.58 (1.22-2.05) | 1.09 (0.80-1.48) |
| Amenable to health care intervention | 31/13 542 (0.2) | 40/135 410 (0.0) | 7.75 (4.85-12.39) | 8.55 (5.27-13.89) | 6.58 (4.02-10.78) | 3.64 (2.10-6.30) | 8.82 (5.38-14.44) | 7.11 (4.42-11.44) | 3.71 (2.08-6.63) |
| Preventable | 44/13 542 (0.3) | 333/135 410 (0.3) | 1.32 (0.97-1.81) | 1.25 (0.91-1.72) | 1.32 (0.96-1.82) | 1.25 (0.90-1.74) | 0.88 (0.62-1.25) | 1.03 (0.75-1.41) | 0.77 (0.53-1.11) |
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; NA, not applicable; OR, odds ratio.
Only specific causes of death with significant between-group differences are depicted. The detailed description of the confounders, including diagnostic codes, is provided in eTable 1 in the Supplement.
Categories with fewer than 5 individuals in any of the cells are not shown.
Definition is from the Office for National Statistics.[29]
Demographic Characteristics of Cohort 2: Individuals With Mild or Moderate to Profound Intellectual Disability (ID) and Their Matched Reference Cohorts
| Characteristic | No. (%) | |||
|---|---|---|---|---|
| Cohort 2: with mild ID | Matched reference cohort | Cohort 2: with moderate to profound ID | Matched reference cohort | |
| Total, No. of individuals | 24 059 | 240 590 | 26 602 | 266 020 |
| Sex | ||||
| Male | 13 649 (56.7) | 136 490 (56.7) | 15 338 (57.7) | 153 390 (57.7) |
| Female | 10 410 (43.3) | 104 100 (43.3) | 11 263 (42.3) | 112 630 (42.3) |
| Age at death, y | ||||
| All individuals | ||||
| Mean (SD) | 52.01 (16.88) | 57.76 (15.72) | 42.16 (21.68) | 57.70 (16.28) |
| Median (range) | 55.08 (0.65-80.53) | 61.09 (1.62-81.81) | 45.47 (0.34-81.58) | 61.65 (0.57-81.88) |
| Male individuals | ||||
| Mean (SD) | 50.88 (17.12) | 56.74 (16.36) | 42.41 (21.48) | 56.94 (16.72) |
| Median (range) | 53.80 (0.65-80.34) | 60.48 (1.62-81.81) | 46.33 (0.55-81.58) | 61.15 (1.74-81.88) |
| Female individuals | ||||
| Mean (SD) | 53.48 (16.45) | 59.41 (14.47) | 41.83 (21.94) | 59.14 (15.31) |
| Median (range) | 56.62 (3.35-80.53) | 62.06 (7.31-81.74) | 44.71 (0.34-80.36) | 62.57 (0.57-81.79) |
| Parental educational level | ||||
| High: academic | 5323 (22.1) | 94 550 (39.3) | 7214 (27.1) | 94 399 (35.5) |
| Middle: upper secondary | 11 355 (47.2) | 96 181 (40.0) | 10 354 (38.9) | 100 482 (37.8) |
| Low: elementary, ≤9 y compulsory | 5032 (20.9) | 31 400 (13.1) | 6081 (22.9) | 45 333 (17.0) |
| Missing data | 2349 (9.8) | 18 459 (7.7) | 2953 (11.1) | 25 806 (9.7) |
| Coexisting diagnoses | ||||
|
| 4975 (20.7) | 15 500 (6.4) | 9211 (34.6) | 15 867 (6.0) |
| Epilepsy | 3809 (15.8) | 2729 (1.1) | 9772 (36.7) | 3344 (1.3) |
| ASD and/or ADHD | 8508 (35.4) | 6744 (2.8) | 7030 (26.4) | 5792 (2.2) |
| Depression and/or anxiety | 6199 (25.8) | 15 302 (6.4) | 3359 (12.6) | 17 356 (6.5) |
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; ICD-10 Chapter XVII: Chromosomal, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Chapter XVII: Congenital malformations, deformations, and chromosomal abnormalities.
Risk of All-Cause, Cause-Specific, and Potentially Avoidable Mortality in Cohort 2: Individuals With Mild or Moderate to Profound Intellectual Disability (ID)
| Category | Cohort 2: ID severity level | Cohort 2: No./total No. (%) | Matched reference cohort, No./total No. (%) | OR (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Crude | Analyses adjusted to potentially moderating factors | Adjusted for all potentially confounding factors | ||||||||
| Parental educational level | Congenital malformations | Epilepsy | ASD and/or ADHD | Depression and/or anxiety | ||||||
| All chapters | Mild ID | 1803/24 059 (7.5) | 4923/240 590 (2.1) | 6.21 (5.79-6.66) | 6.13 (5.71-6.57) | 6.02 (5.61-6.46) | 5.43 (5.04-5.86) | 6.37 (5.93-6.85) | 5.46 (5.07-5.88) | 4.84 (4.46-5.24) |
| All chapters | Mild ID (males) | 1019/13 649 (7.5) | 3042/136 490 (2.2) | 5.65 (5.16-6.20) | 5.55 (5.05-6.09) | 5.48 (4.99-6.01) | 4.89 (4.42-5.40) | 5.81 (5.28-6.40) | 5.04 (4.58-5.55) | 4.41 (3.97-4.90) |
| All chapters | Mild ID (females) | 784/10 410 (7.5) | 1881/104 100 (1.8) | 7.06 (6.34-7.86) | 7.01 (6.29-7.82) | 6.86 (6.15-7.66) | 6.29 (5.60-7.06) | 7.21 (6.45-8.05) | 6.11 (5.45-6.86) | 5.51 (4.87-6.25) |
| All chapters | Moderate to profound | 5081/26 602 (19.1) | 8525/266 020 (3.2) | 13.15 (12.52-13.81) | 13.13 (12.50-13.80) | 11.36 (10.79-11.97) | 8.94 (8.42-9.48) | 14.40 (13.68-15.15) | 13.03 (12.41-13.69) | 8.36 (7.84-8.91) |
| All chapters | Moderate to profound (males) | 2903/15 339 (18.9) | 5584/153 390 (3.6) | 11.35 (10.66-12.09) | 11.31 (10.61-12.05) | 9.86 (9.23-10.55) | 7.93 (7.34-8.56) | 12.70 (11.89-13.57) | 11.13 (10.45-11.86) | 7.66 (7.06-8.32) |
| All chapters | Moderate to profound (females) | 2178/11 263 (19.3) | 2941/112 630 (2.6) | 16.29 (15.06-17.61) | 16.30 (15.07-17.63) | 14.03 (12.91-15.25) | 10.60 (9.65-11.64) | 17.20 (15.87-18.64) | 16.34 (15.11-17.68) | 9.44 (8.54-10.43) |
| Chapter I: Infections | Mild | 38/24 059 (0.2) | 58/240 590 (0.0) | 6.55 (4.35-9.86) | 6.52 (4.32-9.85) | 6.59 (4.35-9.99) | 6.77 (4.36-10.50) | 6.40 (4.23-9.69) | 6.38 (4.14-9.82) | 6.57 (4.11-10.50) |
| Moderate to profound | 146/26 602 (0.6) | 105/266 020 (0.0) | 14.09 (10.95-18.14) | 14.07 (10.91-18.14) | 11.72 (8.94-15.38) | 11.87 (8.69-16.22) | 14.99 (11.58-19.40) | 14.14 (10.97-18.23) | 9.87 (7.10-13.72) | |
| Chapter II: Neoplasms | Mild | 293/24 059 (1.2) | 1791/240 590 (0.7) | 1.72 (1.51-1.96) | 1.71 (1.50-1.95) | 1.70 (1.49-1.94) | 1.59 (1.38-1.83) | 1.76 (1.54-2.00) | 1.70 (1.48-1.94) | 1.59 (1.38-1.84) |
| Moderate to profound | 561/26 602 (2.1) | 3053/266 020 (1.2) | 1.95 (1.77-2.14) | 1.94 (1.76-2.13) | 1.93 (1.75-2.14) | 1.54 (1.37-1.74) | 1.96 (1.78-2.16) | 1.93 (1.76-2.13) | 1.56 (1.39-1.76) | |
| Chapter III: Blood, immune mechanisms | Mild | 11/24 059 (0.1) | 10/240 590 (0.0) | 11.00 (4.67-25.90) | 11.62 (4.88-27.68) | 10.46 (4.37-25.01) | 9.11 (3.52-23.56) | 10.64 (4.41-25.63) | 8.92 (3.51-22.65) | 7.10 (2.63-19.17) |
| Moderate to profound | 25/26 602 (0.1) | 25/266 020 (0.0) | 10.00 (5.74-17.41) | 9.89 (5.66-17.30) | 8.97 (4.93-16.31) | 4.09 (1.82-9.22) | 11.79 (6.65-20.90) | 10.73 (6.15-18.73) | 3.64 (1.57-8.45) | |
| Chapter IV: Endocrine | Mild | 84/24 059 (0.4) | 149/240 590 (0.1) | 5.74 (4.39-7.53) | 5.73 (4.36-7.53) | 5.66 (4.30-7.45) | 5.27 (3.91-7.10) | 5.69 (4.32-7.48) | 5.15 (3.86-6.88) | 4.68 (3.42-6.40) |
| Moderate to profound | 202/26 602 (0.8) | 213/266 020 (0.1) | 9.72 (8.00-11.80) | 9.69 (7.97-11.79) | 9.28 (7.56-11.39) | 8.97 (7.07-11.39) | 10.60 (8.69-12.94) | 9.72 (7.99-11.83) | 8.96 (7.00-11.47) | |
| Chapter V: Mental and behavioral | Mild | 60/24 059 (0.3) | 131/240 590 (0.1) | 4.71 (3.45-6.42) | 4.53 (3.32-6.19) | 4.88 (3.57-6.68) | 3.92 (2.77-5.57) | 4.93 (3.60-6.75) | 3.36 (2.40-4.72) | 3.17 (2.18-4.61) |
| Moderate to profound | 266/26 602 (1.0) | 188/266 020 (0.1) | 15.13 (12.48-18.35) | 15.23 (12.55-18.49) | 15.36 (12.56-18.79) | 10.46 (8.16-13.40) | 15.04 (12.32-18.35) | 14.75 (12.15-17.91) | 9.64 (7.40-12.57) | |
| Chapter VI: Nervous system | Mild | 142/24 059 (0.6) | 152/240 590 (0.1) | 9.42 (7.49-11.85) | 9.57 (7.58-12.07) | 8.90 (7.04-11.26) | 4.58 (3.45-6.08) | 9.15 (7.22-11.60) | 10.29 (8.10-13.08) | 4.55 (3.39-6.09) |
| Moderate to profound | 878/26 602 (3.3) | 277/266 020 (0.1) | 33.34 (29.04-38.29) | 33.83 (29.44-38.88) | 30.64 (26.50-35.43) | 13.19 (11.02-15.80) | 37.16 (32.24-42.83) | 34.96 (30.43-40.16) | 13.70 (11.34-16.54) | |
| Chapter IX: Circulatory system | Mild | 535/24 059 (2.2) | 1287/240 590 (0.5) | 5.25 (4.69-5.88) | 5.24 (4.67-5.87) | 5.17 (4.60-5.80) | 5.00 (4.42-5.66) | 5.24 (4.67-5.88) | 4.74 (4.20-5.35) | 4.44 (3.91-5.06) |
| Moderate to profound | 1020/26 602 (3.8) | 2199/266 020 (0.8) | 5.80 (5.33-6.30) | 5.73 (5.28-6.23) | 5.66 (5.19-6.17) | 5.47 (4.95-6.05) | 5.79 (5.32-6.31) | 5.64 (5.19-6.14) | 5.08 (4.58-5.63) | |
| Chapter X: Respiratory | Mild | 158/24 059 (0.7) | 216/240 590 (0.1) | 7.94 (6.41-9.82) | 7.73 (6.24-9.58) | 8.07 (6.51-10.02) | 6.87 (5.44-8.69) | 7.98 (6.44-9.89) | 6.87 (5.47-8.63) | 6.06 (4.76-7.70) |
| Moderate to profound | 547/26 602 (2.1) | 375/266 020 (0.1) | 15.87 (13.84-18.18) | 15.65 (13.64-17.95) | 13.86 (11.99-16.01) | 13.41 (11.37-15.82) | 16.36 (14.24-18.81) | 15.85 (13.82-18.19) | 11.60 (9.76-13.80) | |
| Chapter XI: Digestive | Mild | 68/24 059 (0.3) | 188/240 590 (0.1) | 3.71 (2.80-4.92) | 3.57 (2.69-4.74) | 3.61 (2.72-4.80) | 3.34 (2.45-4.54) | 3.74 (2.80-4.98) | 3.46 (2.57-4.67) | 3.06 (2.22-4.22) |
| Moderate to profound | 263/26 602 (1.0) | 324/266 020 (0.1) | 8.42 (7.13-9.93) | 8.45 (7.16-9.99) | 7.34 (6.15-8.75) | 6.61 (5.36-8.16) | 8.63 (7.29-10.22) | 8.46 (7.16-10.00) | 6.10 (4.89-7.60) | |
| Chapter XII: Skin | Moderate to profound | 7/26 602 (0.0) | 5/266 020 (0.0) | 14.00 (4.44-44.11) | 16.57 (5.21-52.70) | 12.30 (3.69-40.94) | 9.32 (2.26-38.49) | 15.32 (4.80-48.89) | 12.22 (3.81-39.21) | 9.54 (1.98-45.93) |
| Chapter XIII: Musculoskeletal | Mild | 7/24 059 (0.0) | 33/240 590 (0.0) | 2.13 (0.94-4.84) | 2.13 (0.93-4.85) | 2.10 (0.92-4.82) | 1.94 (0.77-4.85) | 2.14 (0.93-4.95) | 2.22 (0.93-5.25) | 2.21 (0.83-5.87) |
| Moderate to profound | 51/26 602 (0.2) | 40/266 020 (0.0) | 12.75 (8.43-19.29) | 12.56 (8.28-19.05) | 10.52 (6.76-16.37) | 10.04 (6.13-16.46) | 12.95 (8.49-19.75) | 12.92 (8.52-19.60) | 7.74 (4.55-13.17) | |
| Chapter XIV: Genitourinary | Mild | 31/24 059 (0.1) | 29/240 590 (0.0) | 11.19 (6.67-18.77) | 11.61 (6.87-19.62) | 10.77 (6.34-18.28) | 9.47 (5.42-16.54) | 11.19 (6.67-18.77) | 12.04 (7.02-20.66) | 9.12 (5.04-16.52) |
| Moderate to profound | 93/26 602 (0.4) | 51/266 020 (0.0) | 18.80 (13.30-26.58) | 19.21 (13.57-27.21) | 18.86 (13.15-27.05) | 18.79 (12.52-28.20) | 18.14 (12.78-25.77) | 18.70 (13.19-26.51) | 16.59 (10.85-25.34) | |
| Chapter XVII: Malformations, chromosomal | Mild | 38/24 059 (0.2) | 20/240 590 (0.0) | 19.00 (11.06-32.65) | 19.69 (11.30-34.30) | 7.62 (4.34-13.36) | 18.15 (10.11-32.58) | 19.49 (11.13-34.13) | 21.48 (12.29-37.53) | 7.97 (4.16-15.27) |
| Moderate to profound | 548/26 602 (2.1) | 46/266 020 (0.0) | 121.66 (89.77-164.87) | 125.38 (92.44-170.05) | 39.45 (28.64-54.35) | 81.81 (58.71-114.00) | 152.68 (112.12-207.92) | 128.98 (95.15-174.83) | 34.06 (23.72-48.90) | |
| Chapter XVIII: Symptoms, signs | Mild | 36/24 059 (0.2) | 84/240 590 (0.0) | 4.34 (2.93-6.44) | 4.16 (2.80-6.18) | 4.49 (3.01-6.68) | 4.01 (2.60-6.20) | 4.55 (3.04-6.80) | 4.20 (2.77-6.36) | 4.23 (2.68-6.68) |
| Moderate to profound | 75/26 602 (0.3) | 156/266 020 (0.1) | 4.85 (3.68-6.39) | 4.83 (3.66-6.38) | 4.61 (3.43-6.18) | 3.83 (2.67-5.51) | 4.76 (3.57-6.34) | 4.55 (3.44-6.01) | 3.69 (2.53-5.39) | |
| Chapter XIX-XX: External causes | Mild | 293/24 059 (1.2) | 768/240 590 (0.3) | 3.93 (3.43-4.51) | 3.78 (3.29-4.35) | 3.89 (3.39-4.47) | 4.09 (3.54-4.74) | 3.82 (3.30-4.42) | 2.75 (2.37-3.19) | 2.97 (2.53-3.49) |
| Moderate to profound | 301/26 602 (1.1) | 1445/266 020 (0.5) | 2.11 (1.86-2.39) | 2.05 (1.80-2.32) | 2.28 (2.00-2.60) | 2.17 (1.87-2.53) | 2.09 (1.83-2.38) | 1.86 (1.64-2.11) | 2.14 (1.83-2.52) | |
| Potentially avoidable, both amenable and preventable | Mild | 940/24 059 (3.9) | 2788/240 590 (1.2) | 4.20 (3.86-4.57) | 4.12 (3.78-4.48) | 4.11 (3.78-4.48) | 3.69 (3.37-4.04) | 4.15 (3.80-4.53) | 3.46 (3.17-3.78) | 3.09 (2.81-3.41) |
| Moderate to profound | 1747/26 602 (6.6) | 4719/266 020 (1.8) | 4.64 (4.36-4.93) | 4.58 (4.30-4.88) | 4.43 (4.15-4.73) | 3.53 (3.27-3.81) | 4.60 (4.31-4.90) | 4.38 (4.11-4.66) | 3.27 (3.01-3.55) | |
| Amenable to health care intervention | Mild | 663/24 059 (2.8) | 1601/240 590 (0.7) | 5.20 (4.70-5.76) | 5.15 (4.65-5.71) | 5.12 (4.62-5.68) | 4.29 (3.83-4.80) | 5.18 (4.67-5.75) | 4.65 (4.17-5.18) | 3.85 (3.43-4.34) |
| Moderate to profound | 1426/26 602 (5.4) | 2760/266 020 (1.0) | 6.65 (6.19-7.15) | 6.61 (6.15-7.11) | 6.13 (5.68-6.62) | 4.91 (4.49-5.38) | 6.57 (6.10-7.08) | 6.50 (6.04-6.99) | 4.46 (4.06-4.90) | |
| Preventable | Mild | 640/24 059 (2.7) | 2318/240 590 (1.0) | 3.14 (2.85-3.45) | 3.07 (2.79-3.38) | 3.09 (2.81-3.40) | 3.04 (2.75-3.37) | 3.07 (2.78-3.39) | 2.49 (2.25-2.75) | 2.48 (2.22-2.76) |
| Moderate to profound | 897/26 602 (3.4) | 3895/266 020 (1.5) | 2.51 (2.32-2.71) | 2.47 (2.29-2.67) | 2.56 (2.36-2.78) | 2.29 (2.09-2.52) | 2.48 (2.29-2.68) | 2.32 (2.15-2.51) | 2.20 (1.99-2.43) | |
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; OR, odds ratio.
Categories with fewer than 5 individuals in any of the cells are not shown. The detailed description of the confounders, including diagnostic codes, is provided in eTable 1 in the Supplement.
Categories show significant attenuation of risk after adjustment for epilepsy and stratified for epilepsy diagnostic status in eTable 6 in the Supplement.
Definition is from the Office for National Statistics.[29]
Figure. Overall Mortality and Potentially Avoidable Mortality in Young Adults With Mild Intellectual Disability (ID)
Proportional area chart shows higher overall mortality rate among young adults (born 1980-1991) with mild ID (88.6 per 10 000) compared with the matched reference cohort (31.3 per 10 000) as well as between-group comparisons and within-group proportions of the deaths categorized as possibly preventable (36.7% vs 78.5%; odds ratio [OR], 1.32; 95% CI, 0.97-1.81) or amenable to health care interventions (25.8% vs 9.9%; OR, 7.75; 95% CI, 4.85-12.39).